| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 37 | 2024 | 1191 | 9.880 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 442 | 7.990 |
Why?
|
| Hepatitis C, Chronic | 19 | 2023 | 469 | 4.550 |
Why?
|
| Hepatitis C | 15 | 2023 | 547 | 4.070 |
Why?
|
| End Stage Liver Disease | 20 | 2024 | 189 | 3.940 |
Why?
|
| Carcinoma, Hepatocellular | 24 | 2024 | 2172 | 3.860 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 65 | 3.660 |
Why?
|
| Liver Neoplasms | 25 | 2024 | 4814 | 2.860 |
Why?
|
| Antiviral Agents | 18 | 2023 | 1250 | 2.510 |
Why?
|
| Liver Cirrhosis | 32 | 2024 | 1043 | 2.480 |
Why?
|
| Hepacivirus | 13 | 2023 | 421 | 2.450 |
Why?
|
| Waiting Lists | 12 | 2022 | 267 | 2.200 |
Why?
|
| Tissue and Organ Procurement | 6 | 2018 | 235 | 2.140 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 624 | 1.770 |
Why?
|
| Nutrition Surveys | 20 | 2024 | 316 | 1.770 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 698 | 1.750 |
Why?
|
| Tissue Donors | 8 | 2023 | 812 | 1.700 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 598 | 1.550 |
Why?
|
| Fatty Liver | 7 | 2024 | 247 | 1.530 |
Why?
|
| Betacoronavirus | 5 | 2020 | 513 | 1.370 |
Why?
|
| United States | 57 | 2024 | 15776 | 1.340 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2021 | 25 | 1.270 |
Why?
|
| Hospitalization | 13 | 2024 | 2161 | 1.190 |
Why?
|
| Organ Transplantation | 2 | 2020 | 203 | 1.120 |
Why?
|
| Pandemics | 15 | 2024 | 1603 | 1.110 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 139 | 1.080 |
Why?
|
| Graft Survival | 7 | 2023 | 1079 | 0.940 |
Why?
|
| Humans | 135 | 2024 | 270014 | 0.940 |
Why?
|
| Risk Factors | 32 | 2024 | 17824 | 0.930 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 600 | 0.900 |
Why?
|
| Prevalence | 20 | 2024 | 3353 | 0.890 |
Why?
|
| Mortality | 4 | 2021 | 347 | 0.880 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2024 | 186 | 0.860 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 53 | 0.860 |
Why?
|
| Transplant Recipients | 3 | 2021 | 336 | 0.840 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 261 | 0.830 |
Why?
|
| Liver Failure | 3 | 2017 | 141 | 0.810 |
Why?
|
| Retrospective Studies | 42 | 2024 | 39733 | 0.800 |
Why?
|
| Coinfection | 2 | 2023 | 199 | 0.780 |
Why?
|
| Liver | 10 | 2023 | 3069 | 0.770 |
Why?
|
| Drug Overdose | 2 | 2020 | 97 | 0.770 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 87 | 0.750 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 654 | 0.750 |
Why?
|
| Cause of Death | 14 | 2024 | 778 | 0.730 |
Why?
|
| Adult | 51 | 2024 | 81690 | 0.690 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 43 | 0.680 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 318 | 0.630 |
Why?
|
| Probiotics | 1 | 2021 | 241 | 0.630 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 49 | 0.620 |
Why?
|
| Length of Stay | 7 | 2021 | 2000 | 0.610 |
Why?
|
| Liver Diseases | 5 | 2023 | 599 | 0.600 |
Why?
|
| Male | 59 | 2024 | 127911 | 0.570 |
Why?
|
| Gastrectomy | 2 | 2017 | 474 | 0.560 |
Why?
|
| Middle Aged | 48 | 2024 | 90027 | 0.560 |
Why?
|
| DNA, Viral | 2 | 2018 | 753 | 0.560 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 1041 | 0.560 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 76 | 0.550 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 82 | 0.550 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 12 | 0.550 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 331 | 0.530 |
Why?
|
| Transplants | 1 | 2016 | 50 | 0.530 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1232 | 0.530 |
Why?
|
| Secondary Prevention | 1 | 2017 | 309 | 0.520 |
Why?
|
| Female | 58 | 2024 | 148480 | 0.510 |
Why?
|
| Portal Vein | 1 | 2017 | 359 | 0.480 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 286 | 0.480 |
Why?
|
| Hospital Costs | 1 | 2016 | 242 | 0.470 |
Why?
|
| Hepatic Encephalopathy | 4 | 2023 | 90 | 0.470 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 4360 | 0.450 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 380 | 0.440 |
Why?
|
| Health Care Costs | 4 | 2024 | 698 | 0.440 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 68 | 0.420 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 981 | 0.410 |
Why?
|
| Time Factors | 12 | 2021 | 12952 | 0.400 |
Why?
|
| Aged | 27 | 2024 | 73126 | 0.400 |
Why?
|
| Databases, Factual | 8 | 2022 | 2230 | 0.400 |
Why?
|
| Postoperative Complications | 2 | 2017 | 5666 | 0.400 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 2209 | 0.390 |
Why?
|
| HIV Infections | 2 | 2023 | 2152 | 0.370 |
Why?
|
| Patient Readmission | 3 | 2020 | 568 | 0.370 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 180 | 0.360 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 4471 | 0.330 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 503 | 0.320 |
Why?
|
| Risk Assessment | 12 | 2023 | 6752 | 0.320 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 1427 | 0.300 |
Why?
|
| Health Status Disparities | 3 | 2020 | 318 | 0.300 |
Why?
|
| Laparoscopy | 1 | 2017 | 1301 | 0.300 |
Why?
|
| Registries | 4 | 2019 | 2205 | 0.300 |
Why?
|
| Hypothyroidism | 2 | 2020 | 207 | 0.290 |
Why?
|
| Inpatients | 4 | 2020 | 686 | 0.280 |
Why?
|
| Young Adult | 12 | 2024 | 22134 | 0.280 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 5099 | 0.260 |
Why?
|
| Treatment Outcome | 15 | 2023 | 33690 | 0.260 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 416 | 0.260 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 140 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6253 | 0.230 |
Why?
|
| Incidence | 5 | 2021 | 5806 | 0.230 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 49 | 0.230 |
Why?
|
| Preoperative Period | 3 | 2020 | 347 | 0.230 |
Why?
|
| Hepatitis A | 1 | 2024 | 36 | 0.230 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 71 | 0.230 |
Why?
|
| Republic of Korea | 1 | 2024 | 76 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 32 | 0.220 |
Why?
|
| Telemedicine | 2 | 2023 | 551 | 0.220 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 79 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 1731 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 52 | 0.210 |
Why?
|
| Age Distribution | 3 | 2019 | 713 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2024 | 9463 | 0.210 |
Why?
|
| Recurrence | 3 | 2021 | 4873 | 0.210 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 30923 | 0.210 |
Why?
|
| California | 2 | 2020 | 212 | 0.200 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 62 | 0.200 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 32 | 0.200 |
Why?
|
| HIV | 1 | 2023 | 236 | 0.190 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 17 | 0.190 |
Why?
|
| Integrases | 1 | 2023 | 256 | 0.190 |
Why?
|
| Prebiotics | 1 | 2021 | 35 | 0.190 |
Why?
|
| Viremia | 1 | 2022 | 182 | 0.190 |
Why?
|
| Cholestasis | 1 | 2023 | 207 | 0.190 |
Why?
|
| Hypernatremia | 1 | 2021 | 30 | 0.190 |
Why?
|
| Military Personnel | 1 | 2023 | 233 | 0.190 |
Why?
|
| Health Care Rationing | 1 | 2021 | 80 | 0.190 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 84 | 0.180 |
Why?
|
| Cost of Illness | 2 | 2021 | 503 | 0.180 |
Why?
|
| Adolescent | 6 | 2024 | 32646 | 0.180 |
Why?
|
| Biliary Atresia | 1 | 2023 | 201 | 0.180 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 1309 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 42 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2021 | 64 | 0.180 |
Why?
|
| Hyponatremia | 1 | 2021 | 86 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 273 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 153 | 0.180 |
Why?
|
| Peritonitis | 2 | 2017 | 97 | 0.180 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 38 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 372 | 0.180 |
Why?
|
| Tacrolimus | 1 | 2021 | 345 | 0.170 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 223 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 173 | 0.170 |
Why?
|
| Causality | 1 | 2019 | 176 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 115 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2021 | 352 | 0.160 |
Why?
|
| Entamoebiasis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 18 | 0.160 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 244 | 0.160 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 41 | 0.160 |
Why?
|
| Exercise | 3 | 2021 | 1206 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 83 | 0.160 |
Why?
|
| Phenols | 1 | 2019 | 105 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 500 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 2019 | 68 | 0.150 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 68 | 0.150 |
Why?
|
| Methadone | 1 | 2020 | 211 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2020 | 366 | 0.150 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 29 | 0.150 |
Why?
|
| Health Policy | 1 | 2020 | 278 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 350 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 700 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 368 | 0.150 |
Why?
|
| Rifamycins | 1 | 2017 | 32 | 0.150 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 489 | 0.150 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 331 | 0.150 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 27 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 24 | 0.140 |
Why?
|
| Nutritional Support | 1 | 2017 | 79 | 0.140 |
Why?
|
| Carbamates | 1 | 2017 | 81 | 0.140 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 3 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2017 | 55 | 0.140 |
Why?
|
| Bacterial Infections | 2 | 2017 | 508 | 0.140 |
Why?
|
| Clostridium Infections | 1 | 2020 | 262 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 122 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 4318 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 325 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 126 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 307 | 0.130 |
Why?
|
| Income | 1 | 2016 | 229 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 354 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 247 | 0.120 |
Why?
|
| Educational Status | 1 | 2016 | 387 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1296 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 342 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 1426 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 170 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 241 | 0.120 |
Why?
|
| Age Factors | 3 | 2019 | 5448 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 224 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2016 | 261 | 0.110 |
Why?
|
| Heterozygote | 1 | 2017 | 1055 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 822 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2023 | 6204 | 0.110 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 1468 | 0.110 |
Why?
|
| Disease Progression | 6 | 2022 | 6840 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 758 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 601 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1299 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 439 | 0.100 |
Why?
|
| Veterans | 1 | 2023 | 1735 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2021 | 6367 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 774 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7883 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 951 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 399 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 2110 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 89 | 0.090 |
Why?
|
| Medicaid | 2 | 2023 | 305 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 144 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 822 | 0.080 |
Why?
|
| Ascites | 2 | 2023 | 212 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 2389 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 15 | 0.080 |
Why?
|
| Decision Making | 1 | 2016 | 1249 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1808 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 1248 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 2056 | 0.070 |
Why?
|
| Child | 3 | 2024 | 30460 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10382 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2022 | 9288 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 2170 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 1095 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2023 | 13378 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 15172 | 0.070 |
Why?
|
| Survival Rate | 4 | 2020 | 12508 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2024 | 2238 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2024 | 1928 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5250 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3070 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 2295 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 26 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 3160 | 0.060 |
Why?
|
| SEER Program | 2 | 2021 | 1047 | 0.060 |
Why?
|
| Biopsy | 2 | 2023 | 3384 | 0.060 |
Why?
|
| Agent Orange | 1 | 2023 | 4 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 2256 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2023 | 847 | 0.060 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 112 | 0.050 |
Why?
|
| Quality of Life | 1 | 2017 | 4772 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 965 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 101 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 75 | 0.050 |
Why?
|
| Logistic Models | 2 | 2020 | 3438 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2023 | 92 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 175 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 104 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 2325 | 0.050 |
Why?
|
| Prognosis | 4 | 2023 | 22451 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 271 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 98 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 332 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7779 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 313 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 255 | 0.050 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 16 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 4944 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 597 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 318 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 828 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 146 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 16 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 686 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 660 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 237 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2901 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 274 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 103 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 490 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 42 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 629 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 124 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 638 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 179 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 63 | 0.040 |
Why?
|
| Myositis | 1 | 2019 | 86 | 0.040 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 13 | 0.040 |
Why?
|
| Patient Portals | 1 | 2017 | 20 | 0.040 |
Why?
|
| Computer Security | 1 | 2017 | 30 | 0.040 |
Why?
|
| Mutation | 1 | 2017 | 15900 | 0.040 |
Why?
|
| Safety-net Providers | 1 | 2017 | 55 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 185 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 14 | 0.030 |
Why?
|
| Animals | 1 | 2021 | 61707 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 118 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 175 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 676 | 0.030 |
Why?
|
| Risk | 1 | 2020 | 1937 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 188 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 589 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 758 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 592 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 634 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 506 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 649 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 530 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1415 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 728 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 599 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 651 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 2056 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 1287 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 1338 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 930 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2016 | 399 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 957 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 1603 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 15899 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 3023 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 1476 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2019 | 920 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2018 | 1552 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 835 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2026 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2388 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4820 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3897 | 0.020 |
Why?
|
| Palliative Care | 1 | 2019 | 2173 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8671 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 4956 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 13945 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 16984 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 8108 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 10694 | 0.010 |
Why?
|